Sign In
Buy EVOK
$11.00
+0 (+0%)
At Close: Mar 16, 2026
William Hill owner Evoke's losses escalate
03:31am, Thursday, 15'th Aug 2024
William Hill owner Evoke plc reported a 2.2% year-over-year decrease in revenue for the first half of 2024, amounting to £862 million. The company also saw a significant drop in adjusted EBITDA, whic
Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results
08:00am, Tuesday, 13'th Aug 2024
GIMOTI second quarter net product sales grew 47% quarter-over-quarter and 126% year-over-year, indicating an annual run-rate in excess of $10 million
Evoke Pharma, Inc. Supports Gastroparesis Awareness Month
08:30am, Thursday, 08'th Aug 2024
Collaborating with advocacy groups to amplify gastroparesis awareness for millions of patients worldwide Call for action to improve health and access for patients SOLANA BEACH, Calif., Aug. 08, 2024 (
Evoke Pharma, Inc. Announces Reverse Stock Split
08:30am, Tuesday, 30'th Jul 2024
SOLANA BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK) , a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with a
William Hill owner Evoke tumbles after issuing profit warning
04:58am, Thursday, 18'th Jul 2024
Shares in Evoke PLC fell almost 9% after the William Hill owner warned that first-half profits would come in below expectations. Adjusted EBITDA for the first six months of the year are now guided to
Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI
08:30am, Monday, 17'th Jun 2024
Expanded State Medicaid Access for GIMOTI Achieved highest ever monthly GIMOTI prescription fills in May 2024 Promoted former VP of Finance, Mark Kowieski to Chief Financial Officer SOLANA BEACH, Cali
SOLANA BEACH, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with a
Evoke Pharma Reports First Quarter 2024 Financial Results
04:15pm, Tuesday, 14'th May 2024
114% year-over-year increase in net product sales 70% prescriber growth in Q1 2024 compared to Q4 2023 Growing sales metrics reaffirms company's $14M net revenue guidance for 2024
Michael Cline, DO., Medical Director Gastroparesis Clinic, Cleveland Clinic to present Michael Cline, DO., Medical Director Gastroparesis Clinic, Cleveland Clinic to present
Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive Officer
04:15pm, Thursday, 21'st Mar 2024
SOLANA BEACH, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with a
Evoke Pharma, Inc. (EVOK) Q4 2023 Earnings Call Transcript
09:33pm, Thursday, 14'th Mar 2024
Evoke Pharma, Inc. (EVOK) Q4 2023 Earnings Call Transcript
Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
04:05pm, Thursday, 14'th Mar 2024
Fiscal year 2023 net product sales from prescriptions totaled approximately $5.2M, a 107% increase from 2022
Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024
04:10pm, Thursday, 07'th Mar 2024
SOLANA BEACH, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an emphasi
Evoke Pharma Announces Closing of $7.5 Million Public Offering
07:30am, Wednesday, 14'th Feb 2024
Potential for Additional $22.5 Million in the Event of Exercise of Common Warrants in Full Potential for Additional $22.5 Million in the Event of Exercise of Common Warrants in Full
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million
07:30am, Friday, 09'th Feb 2024
SOLANA BEACH, Calif., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with
